News Release

Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students

-- Bedminster, N.J., Office Now Home to nearly 500 Jobs Supporting Company's Growing Hospital Therapies and Autoimmune and Rare Diseases Businesses --

BEDMINSTER, N.J., Oct. 16, 2017 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today joined U.S. Rep. Leonard Lance, R-N.J., to mark the official opening of its Specialty Brands office campus in New Jersey. The new space at 1425 U.S. Route 206, in Bedminster, N.J. is home to a workforce of nearly 500 that supports marketed and development products in the company's hospital therapies and autoimmune and rare diseases businesses.

U.S. Congressman Leonard Lance (NJ-7) joins Mallinckrodt Pharmaceuticals executives, New Jersey state legislators, local dignitaries and members of the Bedminster, N.J., community to officially open Mallinckrodt’s Bedminster Specialty Brands office, which will house a workforce of nearly 500 employees.

"Mallinckrodt is doing important work for patients across the country and world. I am pleased to welcome the Specialty Brands office to Bedminster as well as to meet the team of professionals who are tasked with this critical work," said Congressman Lance. "The life sciences sector in New Jersey is shaping 21st Century health care advancements around the world. Work done at Mallinckrodt's office will help address the unmet medical needs of countless patients in our communities. We need this expertise in New Jersey up and running."

Mallinckrodt's investment in the buildout of its Specialty Brands office includes a complete renovation of 190,000 square feet of office space, with the company occupying more than 80 percent of the building, and design of an open, light-filled work environment that offers employees multiple ways to work and collaborate. In all, the company has added 330 new jobs in Somerset County, N.J., and has designed the site to accommodate potential growth over time.

"Bedminster has proved to be an excellent setting for Mallinckrodt, allowing us to build out a collaborative work space for our New Jersey-based employees, and meet the needs of our fast-transforming business," said Mark Trudeau, Mallinckrodt President and Chief Executive Officer.

The company also announced a $100,000 donation to support the Princeton University Preparatory Program (PUPP), which prepares high-achieving, low-income high school students for admission to, and ongoing success within, higher education. Mallinckrodt's support will fund math-related curriculum and college admission testing preparation, while also enabling university and college site visits and tours for approximately 44 students.

"Mallinckrodt believes strongly in supporting STEM (science, technology, engineering and mathematics) initiatives, so as to create a diverse pipeline of science professionals in areas that are in high demand, within our industry and beyond," said Trudeau.

"We are honored to receive this new support from Mallinckrodt. This gift will directly impact our intensive math curriculum in the summer and provide our PUPP scholars a critical opportunity to visit some of the best colleges in the northeast this fall," said Jason R. Klugman, Ph.D., Director, Princeton University Preparatory Program. "For low-income, first-generation college students, the campus visit is an important part of the college search process and an experience that their families are typically unable to provide. The PUPP college tour helps our scholars see themselves as undergraduates at some of our nation's top colleges and universities."

College visits also foster community among current PUPP Scholars and program alumni who are current undergraduates at a range of institutions, including many that will be visited this fall, such as Colgate University, Middlebury College, Mt. Holyoke College, Trinity College, Union College and Yale University, Klugman said.

To learn more about Mallinckrodt or to explore career opportunities with the company, visit

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


Rhonda Sciarra
Senior Communications Manager

Meredith Fischer
Chief Public Affairs Officer

Government Affairs
Mark Tyndall
Vice President of Government Affairs and Public Policy

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

Daniel J. Speciale, CPA
Director, Investor Relations

 View original content with multimedia:

SOURCE Mallinckrodt Pharmaceuticals